Vnitr Lek 2020, 66(8):490-493 | DOI: 10.36290/vnl.2020.145

How to treat arterial hypertension in obese patients?

Hana Rosolová
Centrum preventivní kardiologie Univerzita Karlova, Lékařská fakulta v Plzni a 2. interní klinika Fakultní nemocnice Plzeň

Obesity (the most common metabolic disease) and arterial hypertension (the most common cardiovascular disease) are often occurring together, which brings very high cardiometabolic risk, i.e. risk for atherosclerotic vascular diseases and type 2 diabetes. Hypertension in obese patients is often resistant to drug treatment, represents the salt sensitive hypertension and many organ damages and other diseases are present. The common pathophysiological mechanisms of the both diseases are mentioned. Those mechanisms stimulate the development of macro- and micro-vascular complications and from those mechanisms arise the management of hypertension in obese patients. Combination of ACE inhibitor and metabolically neutral diuretic indapamide seems to be suitable for the pharmacological treatment of hypertension in obese patient.

Keywords: arterial hypertension, obesity, diuretics, combined antihypertensive treatment.

Published: December 15, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosolová H. How to treat arterial hypertension in obese patients? Vnitr Lek. 2020;66(8):490-493. doi: 10.36290/vnl.2020.145.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze a KV prevence 2018, S1-S22.
    2. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. NEJM 2017; 377: 13-27. Go to original source... Go to PubMed...
    3. Must A, Spadamo J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1992; 282: 1523-1529. Go to original source... Go to PubMed...
    4. Schütten M, Houben A, deLeeuw P, et al. The link between adipose tissue renin‑angiotensin‑aldosteone system signaling and obesity‑associated hypertension. Physiology 2017; 32: 197-209. Go to original source... Go to PubMed...
    5. Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res 2017; 122: 1-7. Go to original source... Go to PubMed...
    6. Schütten M, Houben A, deLeeuw P, et al. The link between adipose tissue renin‑angiotensin‑aldosteone system signaling and obesity‑associated hypertension. Physiology 2017; 32: 197-209. Go to original source... Go to PubMed...
    7. Kawarazaki W, Fujita T. The role of aldosterone in obesity related hypertension. Amer J Hypertens 2016; 29: 415-423. Go to original source... Go to PubMed...
    8. Neter JE, Stam BE, Kok FJ et al. Influence of weight reduction on blood pressure: a meta‑analysis of randomized controlled trials.Hypertension. 2003; 42(5): 878-884.
    9. Rosolová H. Longitudinální primárně preventivní studie ICHS u mužů středního věku v průmyslové populaci. Kandidátská dizertační práce, Plzeň 1990.
    10. Jordan J, et al. Joint statement of the EASO a ESH 2012; 30: 1047.
    11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society. European Heart Journal (2018); doi:10.1093/eurheartj/ehy339. Go to original source... Go to PubMed...
    12. Messerli FH., Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta--analysis of randomized trials. J AmCollCardiol, 2011; 57: 590-600. Go to original source... Go to PubMed...
    13. MRFIT investigators. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990; 82(5): 1616-1628. Go to original source... Go to PubMed...
    14. Dorsch MP, Gillespie BW, Erickson SR et al: Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: A retrospective cohort analysis. Hypertension 2011; 57: 689-694. Go to original source... Go to PubMed...
    15. Leren P, Helgeland A. Oslo Hypertension Study. Drugs 1986; 31(1): 41-45. Go to original source... Go to PubMed...
    16. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004; 43: 963-969. Go to original source... Go to PubMed...
    17. Roush GC, Sica DA: Diuretics for hypertension: A review and update. Amer J Hypertens 2016; 29: 1130-1137. Go to original source... Go to PubMed...
    18. Raggi U, Palumbo P, Moro B, et al. Indapamide in the treatment of hypertension in non‑insulin‑dependent diabetes. Hypertension 1985; 7: 157-160. Go to original source... Go to PubMed...
    19. PATS Collaborating Group. Post‑stroke antihypertensive treatment study Clin Med J 1995; 108: 710-175.
    20. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
    21. Dahlöf B1, Gosse P, Guéret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.Hypertens. 2005 Nov;23(11):2063-70.
    22. De Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009 Apr;20(4):883-92. Go to original source... Go to PubMed...
    23. PROGRESS Collaborative Group: Randomised trial of a perindopril‑based blood pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischemic attack. LANCET 2001;358:1033-1041. Go to original source... Go to PubMed...
    24. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007; 370: 829-840. Go to original source... Go to PubMed...
    25. Zoungas S, et al.: Follow‑up of blood pressure lowering and glucose control in type 2 diabetes. N Engl J Med, doi: 10.1056/NEJMoal1407963. Go to original source...
    26. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug‑resistant hypertension (PATHWAY-2): a randomised, double‑blind, crossover trial. Lancet 2015;386:2059-2068. Go to original source... Go to PubMed...
    27. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze a KV prevence 2018, S1-S22.
    28. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study (CAMUS). Journal of Human Hypertension 2004;18:669-675. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.